Exosomal DNA Aptamer Targeting α-Synuclein Aggregates Reduced Neuropathological Deficits in a Mouse Parkinson’s Disease Model

Xiaoxi Ren,Yun Zhao,Fenqin Xue,Yan Zheng,Haixia Huang,Wei Wang,Yongchang Chang,Hui Yang,Jianliang Zhang
DOI: https://doi.org/10.1016/j.omtn.2019.07.008
2019-09-01
Abstract:<p>The α-synuclein aggregates are the main component of Lewy bodies in Parkinson's disease (PD) brain, and it showed immunotherapy could be employed to alleviate α-synuclein aggregate pathology in PD. Recently we have generated DNA aptamers that specifically recognize α-synuclein. In this study, we further investigated the <em>in vivo</em> effect of these aptamers on the neuropathological deficits associated with PD. For efficient delivery of the aptamers into the mouse brain, we employed modified exosomes with the neuron-specific rabies viral glycoprotein (RVG) peptide on the membrane surface. We demonstrated that the aptamers were efficiently packaged into the RVG-exosomes and delivered into neurons <em>in vitro</em> and <em>in vivo</em>. Functionally, the aptamer-loaded RVG-exosomes significantly reduced the α-synuclein preformed fibrils (PFF)-induced pathological aggregates, and rescued synaptic protein loss and neuronal death. Moreover, intraperitoneal administration of these exosomes into the mice with intra-striatally injected α-synuclein PFF reduced the pathological α-synuclein aggregates and improved motor impairments. In conclusion, we demonstrated that the aptamers targeting α-synuclein aggregates could be effectively delivered into the mouse brain by the RVG-exosomes and reduce the neuropathological and behavioral deficits in the mouse PD model. This study highlights the therapeutic potential of the RVG-exosome delivery of aptamer to alleviate the brain α-synuclein pathology.</p>
What problem does this paper attempt to address?